Publications by authors named "B Mishkin"

Article Synopsis
  • This systematic review and meta-analysis assessed the effectiveness and safety of biologic therapies for patients with steroid-refractory microscopic colitis (MC).
  • A total of 376 studies were screened, resulting in 13 articles focused on 78 patients, showing remission rates of approximately 66% at 3-6 weeks and 54% at 12-16 weeks, with a 100% clinical response rate initially but a drop to around 67% later on.
  • The study found a significant incidence of medication discontinuation (16.1%) as the most common adverse event, and concluded that while there is low-quality evidence supporting the short-term use of biologics, more rigorous research is needed to clarify their long-term efficacy
View Article and Find Full Text PDF

Ulcerative colitis (UC) is a chronic inflammatory disorder that requires sustained treatment for optimal outcomes. The 5-aminosalicylate (5-ASA) class of medications are first-line for the treatment of mild-to-moderate UC but suffer from suboptimal adherence rates in real-world settings. This review summarizes the literature on adherence and patient preference to 5-ASA in patients with UC.

View Article and Find Full Text PDF

The coastal Pacific Northwest USA hosts thousands of deep-seated landslides. Historic landslides have primarily been triggered by rainfall, but the region is also prone to large earthquakes on the 1100-km-long Cascadia Subduction Zone megathrust. Little is known about the number of landslides triggered by these earthquakes because the last magnitude 9 rupture occurred in 1700 CE.

View Article and Find Full Text PDF

In randomized clinical trials, a data monitoring committee (DMC) is often appointed to review interim data to determine whether there is early convincing evidence of intervention benefit, lack of benefit or harm to study participants. Because DMCs bear serious responsibility for participant safety, their members may be legally liable for their actions. Despite more than three decades of experiences with DMCs, the issues of liability and indemnification have yet to receive appropriate attention from either government or industry sponsors.

View Article and Find Full Text PDF